[ sulge aken ]
| Elulookirjeldus (CV) | ||
| 1. | Eesnimi | Ade |
| 2. | Perekonnanimi | Kallas |
| 3. | Töökoht | Tartu Ülikool Molekulaar- ja Rakubioloogia instituut Riia 23 Tartu 51010 |
| 4. | Ametikoht | Teadur |
| 5. | Sünniaeg | 13.03.1970 (päev.kuu.aasta) |
| 6. | Haridus | Tartu Ülikool, Farmaatsia instituut, magistriõpe ja doktoriõpe farmaatsia erialal; Tartu Ülikool, Molekulaar- ja rakubioloogia instituut, järeldoktoriõpe |
| 7. | Teenistuskäik | 2005- TÜ Molekulaar- ja rakubioloogia instituut, teadur 2003-2005 TÜ Molekulaar- ja rakubioloogia instituut, erakorraline teadur 1995 - 2003 TÜ farmaatsia instituut, farmatseutilise tehnoloogia assistent (0,5) 1998 - 2003 TÜ farmaatsia instituut, farmaatsia teadur (0,5) |
| 8. | Teaduskraad | Farmaatsiadoktor |
| 9. | Teaduskraadi välja andnud asutus, aasta |
Tartu Ülikool, 2002 |
| 10. | Tunnustused | Noore teadlase preemia 2005 hemofiilia-alaste uuringute teostamiseks, finantseerija ja väljaandja firma Bayer (USA), projekti pealkiri: "The effect of transforming growth factor beta in plasma derived factor VIII preparation on immune system of haemophilia A mice" |
| 11. | Teadusorganisatsiooniline ja –administratiivne tegevus |
Eesti Hemofiiliaühingu president alates 1992.a.; Euroopa Hemofiilia Konsortsiumi juhatuse liige alates 2003.a. |
| 12. | Juhendamisel kaitstud väitekirjad |
|
| 13. | Teadustöö põhisuunad | Immuunvastus VIII hüübimisfaktori vastu hemofiilia A haiguse korral |
| 14. | Jooksvad grandid | ETF grant nr 5454 (2003-2005), Immuunvastus VIII hüübimisfaktori vastu hemofiilia A haiguse korral; The Baxter Grant for Coagulation Research in the Nordic countries 2005. Projekt: "Mechanism of immune tolerance induction against coagulation factor VIII in factor VIII deficient mice"; Haemophilia Award Programm, finantseerija Bayer, "The effect of transforming growth factor beta in plasma derived factor VIII preparation on immune system of haemophilia A mice" (2005-2006) |
| 15. | Teaduspublikatsioonid |
Kallas A, Pooga M, Benhida A, Jacquemin M, Saint-Remy J-M- Epitope specificity of anti-FVIII antibodies during immune tolerance therapy with Factor VIII preparation containing von Willebrand factor. Thrombosis Research 2002; 107/6 pp. 291-302 Kallas A, Talpsep T, Everaus H. Changes in epitope specificity and distribution of IgG subtypes of FVIII antibodies during immune tolerance therapy (ITT) in hemophilia A patients with FVIII antibodies – a case report. In Scharrer I., Schramm W. (eds.) 31st Hemophilia Symposium. Springer Verlag, Berlin Heidelberg, 2001, pp. 23-40 Kallas A, Talpsep T. The assay of von Willebrand factor collagen binding activity: The clinical application. Annals of Hematology 2001; 80 (8): 466-471 Kallas A, Talpsep T. Von Willebrand Factor in Factor VIII concentrates protects Factor VIII neutralisation by Factor VIII antibodies of haemophilia A patients. Haemophilia 2001; 7 (4): 375-380 Kallas A, Everaus H, Talpsepp T. Functional activity and chain specificity of factor VIII antibodies of Estonian haemophilia A patients. In F.H. Herrmann (ed): Molekulare (DNA) Diagnostik Hereditärer Hämostasedefekte. Pabst Science Publishers, Lengerich, 1999, pp. 36-42 Kallas A, Everaus H. Ülevaade desmopressiini kasutamisest verehüübimishäirete ravis. Eesti Arst 1998; 2: 119-126 Kallas A, Everaus H, Schröder H, Hermann F.H. Situation of Haemophilia in Estonia. In F.H.Herrmann (ed): Molekulärgenetik Hereditärer Hämostasedefekte. Pabst Science Publishers, Lengerich, 1997: pp. 24-28 Kallas A, Viires M, Everaus H, Hinrikus T. Faktor VIII – von Willebrandi faktori kompleks hemofiilia A asendusteraapias kasutatavates erinevates faktor VIII preparaatides. Eesti Arst 1997; 5: 417-424 |
viimati muudetud: 07.10.2005
| Curriculum Vitae (CV) | ||
| 1. | First Name | Ade |
| 2. | Surname | Kallas |
| 3. | Institution | University of Tartu Institute of Molecular and Cell Biology Riia Str. 23 Tartu 51010 Estonia |
| 4. | Position | Scientist-researcher |
| 5. | Date of birth | 13.03.1970 (day.month.year) |
| 6. | Education | University of Tartu, Department of Pharmacy, master degree studies and doctoral studies University of Tartu, Institute of Molecular and Cell Biology, Post-doctoral studies |
| 7. | Research and professional experience |
2005- University of Tartu, Institute of Molecular and Cell Biology, scientist-researcher 2003-2005 University of Tartu, Institute of Molecular and Cell Biology, researcher, post-doctoral fellow 1995-2003 University of Tartu, Department of Pharmacy, assistant 1998-2003 University of Tartu, Department of Pharmacy, researcher |
| 8. | Academic degree | Doctor of Pharmaceutical Sciences |
| 9. | Dates and sites of earning the degrees |
University of Tartu, 2002 |
| 10. | Honours/awards | Early Career Investigator Award of Bayer Hemophilia Award Program 2005 for the project entitled "The effect of transforming growth factor beta in plasma derived factor VIII preparation on immune system of haemophilia A mice" (2005-2006) |
| 11. | Research-administrative experience |
President of Estonian Haemophilia Society since 1992; Steering committee member of the European Haemophilia Consortium since 2003 |
| 12. | Supervised dissertations | |
| 13. | Current research program | Immune response against coagulation factor VIII in haemophilia A |
| 14. | Current grant funding | Grant of Estonian Science Foundation No 5454 entitled "Immune response to coagulation factor VIII in haemophilia A" (2003-2005); The Baxter Grant for Coagulation Research in the Nordic countries 2005. Project: Mechanism of immune tolerance induction against coagulation factor VIII in factor VIII deficient mice; Haemophilia Award Programm sponsored by Bayer, Project "The effect of transforming growth factor beta in plasma derived factor VIII preparation on immune system of haemophilia A mice" (2005-2006) |
| 15. | List of most important publications |
Kallas A, Pooga M, Benhida A, Jacquemin M, Saint-Remy J-M- Epitope specificity of anti-FVIII antibodies during immune tolerance therapy with Factor VIII preparation containing von Willebrand factor. Thrombosis Research 2002; 107/6 pp. 291-302 Kallas A, Talpsep T, Everaus H. Changes in epitope specificity and distribution of IgG subtypes of FVIII antibodies during immune tolerance therapy (ITT) in hemophilia A patients with FVIII antibodies – a case report. In Scharrer I., Schramm W. (eds.) 31st Hemophilia Symposium. Springer Verlag, Berlin Heidelberg, 2001, pp. 23-40 Kallas A, Talpsep T. The assay of von Willebrand factor collagen binding activity: The clinical application. Annals of Hematology 2001; 80 (8): 466-471 Kallas A, Talpsep T. Von Willebrand Factor in Factor VIII concentrates protects Factor VIII neutralisation by Factor VIII antibodies of haemophilia A patients. Haemophilia 2001; 7 (4): 375-380 Kallas A, Everaus H, Talpsepp T. Functional activity and chain specificity of factor VIII antibodies of Estonian haemophilia A patients. In F.H. Herrmann (ed): Molekulare (DNA) Diagnostik Hereditärer Hämostasedefekte. Pabst Science Publishers, Lengerich, 1999, pp. 36-42 Kallas A, Everaus H. Ülevaade desmopressiini kasutamisest verehüübimishäirete ravis. Eesti Arst 1998; 2: 119-126 Kallas A, Everaus H, Schröder H, Hermann F.H. Situation of Haemophilia in Estonia. In F.H.Herrmann (ed): Molekulärgenetik Hereditärer Hämostasedefekte. Pabst Science Publishers, Lengerich, 1997: pp. 24-28 Kallas A, Viires M, Everaus H, Hinrikus T. Faktor VIII – von Willebrandi faktori kompleks hemofiilia A asendusteraapias kasutatavates erinevates faktor VIII preparaatides. Eesti Arst 1997; 5: 417-424 |
last updated: 07.10.2005
[ sulge aken ]